Metabolic and endocrine disturbances in psychiatric disorders: A multidisciplinary approach to appropriate atypical antipsychotic utilization

Primary Psychiatry

Volumn 12, Issue 10, 2005, Pages 1-15

  Culpepper, Larry ^a,b,c   Henderson, David ^b,c,d,e,f   Lee, Scott ^b,c,g,h,i   Littrell, Kimberly ^b,e,f,j   Newcomer, John W ^b,c,e,f,i,k   Rasgon, Natalie ^b,c,f,i,l,m  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Eli Lilly ^*  (Switzerland)

^c PFIZER INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ASTRAZENECA   (United Kingdom)

^f BRISTOL MYERS SQUIBB   (United States)

^g LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^h Aventis

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j GEORGIA STATE UNIVERSITY   (United States)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m ABBOTT LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; INSULIN; LIPID; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ALGORITHM; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG UTILIZATION; DYSLIPIDEMIA; ENDOCRINE DISEASE; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; INSULIN RESISTANCE; INSULINEMIA; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; MORBIDITY; MORTALITY; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 27444446715     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004;89(6):2526-2539.
2. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med. 2004;116(suppl 5A):2S-10S.
3. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129-1134.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-l607.
6. Schinner S, Scherbaum WA, Botnstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med. 2005;22(6):674-682.
7. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
8. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(suppl 1):S37-42.
10. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611-619.
11. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;Sep 12: [Epub ahead of print].
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
13. Goodpaster BH, Krishnaswami S, Harris TB, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med. 2005;165(7):777-783.
14. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427-436.
15. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24:S7-S14.
16. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27:596-601.
17. Sokal J, Messias E, Dickerson FB, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis. 2004;192:421-427.
18. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237-252.
19. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
20. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36(4):239-245.
21. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
22. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000;321(7259):483-484.
23. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850.
24. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194.
25. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004;192(1):19-27.
26. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29(3):697-701.
27. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999;187(8):496-502.
28. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50(6):827-829.
29. Lyons MJ, Bar JL, Kremen WS, Toomey R, et al. Nicotine and familial vulnerability to schizophrenia: a discordant twin study. J Abnorm Psychol. 2002;111(4):687-693.
30. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58(6):565-572.
31. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
32. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-930.
33. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328-335.
34. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:56l-566.
35. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58:1172-1176.
36. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002;22:236-243.
37. Fuller MA, Shermock KM, Seek M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23:1037-1043.
38. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-1139.
39. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:(suppl 1:)1-93.
40. Buse JB, Cavaszoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56(2):164-170.
41. Abilify (package insert). Otsuka Pharmaceutical Co, Ltd (Tokyo) and Bristol-Myers Squibb (Princeton, NJ); 2002.
42. Geodon (package insert). New York, NY: Pfizer, Inc.; 2002.
43. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(10):1837-1847.
44. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35(6):205-219.
45. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1000;156:1086-1696.
46. Leiberman JA, Stroup TS, McEvoy JT, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005; September 19, 2005 (10.1056/NEJMoa051688).
47. Weiden PJ, Mackwell JA, McDonnelll DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
48. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and rispendone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41(3):337-343.
49. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216-1223.
50. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62-69.
51. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296.
52. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother. 2003;37:1849-1857.
53. Fleischhacker WW, Nasrallah H, Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
54. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111:716-723.
55. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-52.
56. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735-44.
57. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65(6):857-863.
58. Henderson DC, Caglieto E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19-28.
59. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345.
60. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-981.
61. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121.
62. Curtis V. Women are not the same as men: specific clinical issues for female patients with bipolar disorder. Bipolar Disord. 2005;7(suppl 1):16-24.
63. Leibenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry. 1996;153(2):163-173.
64. Leibenluft E. Women and bipolar disorder: an update. Bull Menninger Clin. 2000;64(1):5-17.
65. Rasgon N, Bauer M, Glenn T, Elman S, Whybrow PC. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003;5(1):48-52.
66. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
67. Tondo L, Baldessarini RJ. Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry. 1998;155(10):1434-1436.
68. McElroy SL, Strakowski SM, Keck PE Jr, Tugrul KL, West SA, Lonczak HS. Differences and similarities in mixed and pure mania. Compr Psychiatry. 1995;36(3):187-194.
69. Benazzi F. Gender differences in bipolar II and unipolar depressed outpatients: a 557-case study. Ann Clin Psychiatry. 1999;11(2):55-59.
70. Rasgon N, Bauer M, Grof P, Gyulai L, et al. Sex-specific self-reported mood changes by patients with bipolar disorder. Psychiatr Res. 2005;39(1):77-83.
71. Blehar MC, DePaulo JR Jr, Gershon ES, Reich T, Simpson SG, Nurnberger JI Jr. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull. 1998;34(3):239-243.
72. Parry BL, Hauger R, LeVeau B, et al. Circadian rhythms of prolactin and thyroid-stimulating hormone during the menstrual cycle and early versus late sleep deprivation in premenstrual dysphoric disorder. Psychiatry Res. 1996;62(2):147-160.
73. Bauer M, London ED, Silverman DH, Rasgon N, Kirchheiner J, Whybrow PC. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003;36(suppl 3):S215-S221.
74. Polycystic ovarian syndrome. The National Women's Health Center, US Department of Health and Human Services. Available at: www.women-shealth.gov. Accessed September 2005.
75. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853-861.
76. Bauer J, Jarre A, Klingmuller D, Elger CE. Polycystic ovary syndrome in parients with focal epilepsy: a study in 93 women. Epilepsy Res. 2000;41(2):163-167.
77. Duncan S. Polycystic ovarian syndrome in women with epilepsy: a review. Epilepsia. 2001;42(suppl 3):60-65.
78. Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord. 2005;7(3):246-259.
79. Hopkinson ZE, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology. BMJ. 1998;317(7154):329-332.
80. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132(12):989-993.
81. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(suppl 1):53-67.
82. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55-68.
83. Melkerrson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66:761-767.
84. Halbreich U, Shen J, Panaro V. Are chronic psychiatric patients at increased risk for developing breast cancer? Am J Psychiatry. 1996;153(4):559-560.
85. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001;62(12):923-924.
86. Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol. 2001;86(4):376-380.
87. Liu-Seifert H, Kinon BJ, Ahl J, Lamberson S. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci. 2004;1032:297-298.
88. Shaarawy M, Nafei S, Abul-Nasr A, el-Sharkawy S, Younis A. Circulating nitric oxide levels in galactorrheic, hyperprolactinemic, amenorrheic women. Fertil Steril. 1997;68(3):454-459.
89. Wallaschofski H, Kobsar A, Koksch M, et al. Prolactin receptor signaling during platelet activation. Prolactin receptor signaling during platelet activation. Horm Metab Res. 2003;35(4):228-235.
90. Wallaschofski H, Eigenthaler M, Kiefer M, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol. 2003;23(5):479-483.
91. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(suppl):S75-S86.
92. Ahl J, Kinon BJ, Liu-Seifert H. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ann N Y Acad Sci. 2004;1032:289-290.
93. American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Washington, DC: American Psychiatric Association; 2004.
94. American Urological Association, Inc. The Management of Benign Prostatic Hyperplasia. Baltimore, MD: American Urological Association; 2003.
95. Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001;58(9):861-868.
96. Katzelnick D, Simon G, Pearson S, Manning W, Kobak K. Depression management programs. Arch Fam Med. 2000;9(8):689-770.
97. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61(10):1042-1049.
98. Katon WJ, Roy-Byrne P, Russo J, Cowley D. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry. 2002;59(12):1098-1104.
99. Druss BG, Rosenheck RA. Locus of mental health treatment in an integrated service system. Psychiatr Serv. 2000;51(7):890-892.
100. Druss BG, Rosenheck RA. Mental disorders and access to medical care in the United States. Am J Psychiatry. 1998;155(12):1775-777.
101. Druss BG, Rosenheck RA, Desai MM, Perlin JB. Quality of preventive medical care for patients with mental disorders. Med Care. 2002;40(2):129-136.
102. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: Practice Patterns and Knowledge of Psychiatrists. J Clin Psychopharmacol. 2004;24(suppl):S1-S6.
103. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15-31.
104. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53(11):1028-1042.